- Home
- III vs IPHA Comparison
III vs IPHA Comparison
Compare III & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- III
- IPHA
- Stock Information
- Founded
- III 2006
- IPHA 1999
- Country
- III United States
- IPHA France
- Employees
- III N/A
- IPHA N/A
- Industry
- III Professional Services
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- III Consumer Discretionary
- IPHA Health Care
- Exchange
- III Nasdaq
- IPHA Nasdaq
- Market Cap
- III 161.3M
- IPHA 175.5M
- IPO Year
- III 2007
- IPHA 2019
- Fundamental
- Price
- III $3.18
- IPHA $2.00
- Analyst Decision
- III Buy
- IPHA Strong Buy
- Analyst Count
- III 1
- IPHA 1
- Target Price
- III $3.50
- IPHA $11.50
- AVG Volume (30 Days)
- III 98.1K
- IPHA 9.4K
- Earning Date
- III 11-07-2024
- IPHA 09-12-2024
- Dividend Yield
- III 5.66%
- IPHA N/A
- EPS Growth
- III N/A
- IPHA N/A
- EPS
- III N/A
- IPHA N/A
- Revenue
- III $266,491,000.00
- IPHA $36,202,722.00
- Revenue This Year
- III N/A
- IPHA N/A
- Revenue Next Year
- III $11.73
- IPHA $102.87
- P/E Ratio
- III N/A
- IPHA N/A
- Revenue Growth
- III N/A
- IPHA N/A
- 52 Week Low
- III $2.92
- IPHA $1.81
- 52 Week High
- III $4.98
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- III 46.88
- IPHA 41.71
- Support Level
- III $3.13
- IPHA $1.94
- Resistance Level
- III $3.25
- IPHA $2.10
- Average True Range (ATR)
- III 0.07
- IPHA 0.08
- MACD
- III 0.00
- IPHA -0.01
- Stochastic Oscillator
- III 20.83
- IPHA 16.00
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.